 FORT LAUDERDALE, Fla., March 15, 2021 GLOBE NEWSWIRE -- Motus GI Holdings, Inc., NASDAQ: MOTS Motus GI or the Company, a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the Pure-Vu System. The study is evaluating the clinical and economic outcomes using the Pure-Vu System in patients with emergent lower gastrointestinal bleeding that are evaluated and treated in the Intensive Care Unit ICU or the rapid inpatient endoscopy suite. 